Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Why Novo Nordisk is parting ways with Hims & Hers. To catch full episodes of all The Motley Fool's free podcasts, check out ...

LifeMD is a fast-growing, profitable telehealth company with strong partnerships. Click here to read why LFMD stock is a Buy.

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...